Data investigation

What Tripling the Dose Buys

A higher semaglutide dose produced 18.7% weight loss against 15.6% on the standard dose. Three extra percentage points is the benefit; the costs are in the safety table.

By Nora Bissett · Pricing Editor
Editorially reviewed. Not medical advice · How we verify contentLast reviewed
7 min read·2 citations

A higher dose of semaglutide, 7.2 mg, was tested head to head against the standard 2.4 mg[2] in 1,407 people over 72 weeks. It produced 18.7% weight loss against 15.6%.[1] Three extra percentage points is the benefit. The costs are in the safety table, and one of them is a side effect that is far less common at the standard dose.

What the trial did

Adults with a BMI of 30 or above and without diabetes were randomized five-to-one-to-one across 95 centers in 11 countries: 1,005 to semaglutide 7.2 mg, 201 to 2.4 mg, and 201 to placebo, for 72 weeks. Participants averaged 47 years old, 113 kg, and a BMI of 39.9, and 73.7% were women.

The lopsided allocation is deliberate. The question is what the new dose does, so most participants go there; the comparison arms only need to be large enough to anchor it.

STEP UP at 72 weeks. The 2.4 mg column is the one that matters for this decision.[1]
7.2 mg2.4 mgPlacebo
Weight change−18.7%−15.6%−3.9%
Gastrointestinal events70.8%61.2%42.8%
Dysaesthesia22.9%6.0%0.5%
Serious adverse events6.8%10.9%5.5%

Against the standard dose, the higher one gave an estimated 3.1 percentage points more weight loss (95% CI −4.7 to −1.6) and 2.4 times the odds of reaching a 25% reduction (95% CI 1.6 to 3.5). Waist circumference fell 11.7 cm more than placebo.

The side effect that is new at this dose

Dysaesthesia (abnormal, often unpleasant sensation, typically tingling or altered touch) occurred in 22.9% of the 7.2 mg group, against 6.0% at 2.4 mg and 0.5% on placebo. That is nearly one in four. It is the only finding in this table that is not an ordinary feature of the drug class, and it scales steeply with dose.

Gastrointestinal effects also rose (70.8% against 61.2%), but those are familiar, expected, and mostly fade. An unfamiliar sensory effect appearing in a quarter of people at a higher dose is a different kind of information, and it deserves to be named rather than folded into a total.

Three more percentage points of weight loss, and seventeen more of altered sensation.

The trial’s own interpretation is that the higher dose retained a favorable risk-benefit profile. That may well be right for someone who has not reached their goal at 2.4 mg and for whom the extra loss matters. It is a judgment rather than a measurement, and a reader given both columns can make their own.

The row that goes the other way

Serious adverse events were lower at 7.2 mg (6.8% against 10.9% at 2.4 mg). Reported alone, that reads as the higher dose being safer, which is almost certainly wrong.

The 2.4 mg arm contained 201 people against 1,005 at the higher dose. In a group that size, a handful of unrelated events shifts the percentage by whole points, and 10.9% versus 6.8% is within what chance produces. We include the row anyway. Leaving out inconvenient numbers is the practice this register documents in sellers, and the rule applies to results that favor a drug as much as to ones that do not.

Reading the 2.4 mg column

The standard dose achieved −15.6% here, against the −14.9% everyone remembers from STEP 1. Those are different trials with different participants and different placebo arms, and setting them side by side is a comparison we decline to make. What the 15.6% is good for is the comparison the trial was designed for: against 7.2 mg, in the same people, at the same time.

That is the value of an active-controlled design. Most trials answer “is this better than nothing.” This one answers “is this better than what you would otherwise be prescribed,” which is the question a patient faces.

Two closing notes. The trial was funded by Novo Nordisk, which makes semaglutide. And for what the higher dose costs in dollars rather than side effects, see what 7.2 mg costs.

STEP UP tested the approved product,[2] and its result does not transfer to compounded semaglutide. If that is what you buy, the seller sets both the dose range and how price follows dose. KERNX Health charges one monthly price across semaglutide doses from 0.22 to 2.5 mg weekly. Recovery Delivered charges more as the dose climbs, and Luma Health Co publishes a price for every dose, so the cost of each step is visible in advance. At You4You a month of compounded semaglutide is $180 to $200 at 0.25 mg and $280 to $300 at 2.5 mg, its top dose. Doko MD also prices each four-week supply by dose, but its steps are small: $94 at 0.25 mg a week and $116 at 2.4 mg, with shipping extra.

Some sellers carry both sides of that line. Effecty charges one price at every dose of its compounded semaglutide and also lists brand Wegovy and Ozempic, so a move from the compounded drug to the approved product that STEP UP studied would not mean starting over with a new seller. Found also charges one price at every dose of its compounded semaglutide and prescribes the brand-name pens and pills, Foundayo included.

PrescribedRX, Whoosh Wellness and Nirwana Health charge the same at every dose, and Basal Health does the same for the one drug it sells, compounded tirzepatide. The Aesthetic Concierge bills in five-week blocks, which changes the arithmetic of any monthly comparison. None of that is a reason to move up a dose; that call belongs to your prescriber.

Frequently Asked Questions

In STEP UP, 18.7% against 15.6% on the standard 2.4 mg dose over 72 weeks. That is an estimated 3.1 percentage points more, with 2.4 times the odds of reaching a 25% reduction.
Gastrointestinal events rose from 61.2% to 70.8%, and dysaesthesia (abnormal or unpleasant sensation, usually tingling) rose from 6.0% to 22.9%. That second one affects nearly one in four people at the higher dose.
Altered or unpleasant sensation, typically tingling or changed sensitivity to touch. It occurred in 0.5% of the placebo group, so it is dose-related rather than a background complaint.
They were lower (6.8% against 10.9%), but the standard-dose arm held only 201 people against 1,005, so that difference is within what chance produces in a group that size.
That depends on how much the extra three percentage points matter to you and how you weigh a one-in-four chance of altered sensation. The trial calls the balance favorable, which is a judgment rather than a measurement.

References

  1. 1.Wharton S, Freitas P, Hjelmesæth J, et al. Once-weekly semaglutide 7·2 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial The Lancet Diabetes & Endocrinology. 2025. PMID: 40961952.
  2. 2.Novo Nordisk WEGOVY (semaglutide) injection and tablets — prescribing information (sections 2.2, 3) DailyMed, U.S. National Library of Medicine. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b

Five Clicks Instead of a Quarter Milligram

One in five people on the label's titration schedule quit because of gut side effects. On a slower schedule it was one in fifty, at the same final dose, with the same results.

7 min read

The Top Dose Keeps Not Being Worth It

Orforglipron beat an SGLT2 inhibitor on blood sugar and lost badly on tolerability: one in five stopped taking it. And its top dose is the third in a row, across three trials, to buy almost nothing.

7 min read

One Injection Instead of Twenty-Eight

Someone on basal-bolus insulin injects roughly 28 times a week. A trial tested replacing that with one weekly combination injection, matching blood sugar control while cutting serious hypoglycemia by 88%.

6 min read

More Effect Without More Side Effects

Almost every result in this field trades benefit against harm. Adding cagrilintide to semaglutide produced 6.5 percentage points more weight loss with gut side effects at 53% against 51%.

6 min read

Newer Is Not Stronger

Survodutide has a new mechanism and phase 3 results in the NEJM. It produced 13.0% weight loss at 76 weeks, and its higher dose caused gut side effects in nearly nine of ten participants while losing only 0.8 points more weight than the lower dose.

7 min read

What 262 Trials Say Together

262 trials, 99,791 people, 19 drugs, every result graded. Three of its findings cut against how this field is described, starting with the fact that the drug with the mortality evidence is not the one that takes off the most weight.

9 min read

Where to get GLP-1 online, safely: sellers our editors have checked

These are telehealth sellers our editors have checked. For each one we hold a price, the form the drug comes in, and the states it reaches.

No insurance needed · vetted by our editors

Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more

6.4

Bodybuilding Health+

Seeing what it charges before you answer any medical questions

9.0

YourEra

Semaglutide at $99/month, well below the typical price

8.7

Eden

Coverage in all 50 states, which most sellers will not confirm

About this analysis

GLP Watchdog publishes independently. Each seller in our dataset is checked against that seller's own website, and the dataset is updated continuously. Read our full methodology →